Functional Testing & Monitoring
Whether you're preparing for treatment, navigating it now, or focused on long-term resilience and risk reduction, testing is one of the most powerful tools we have.
This page covers the functional and advanced oncology tests I use to build a clearer clinical picture, including how I interpret standard labs through a functional lens, what specialty testing can reveal that conventional panels miss, and how ongoing monitoring across the course of our work together keeps your health picture current.
Better information leads to better decisions.
Testing That Goes Further
Most standard lab results are designed to rule out disease - not to optimize function. A “normal” result that falls within the reference range tells you that you're not in crisis. It doesn't tell you whether your nutrient levels are adequate for someone in cancer treatment, whether your hormones are metabolizing efficiently, or whether your body has the metabolic reserves to tolerate what's ahead.
Why Standard Testing Isn't Always Enough
Reference ranges are built from population averages. They identify disease - they're not designed to identify the functional insufficiencies that affect how well you tolerate treatment, recover from it, or reduce your risk of recurrence.
Vitamin D is a clear example. A level of 52 nmol/L sits within the standard "normal" range in most labs. For someone in active cancer treatment or working to reduce recurrence risk, the evidence suggests a functional target closer to 100–150 nmol/L is more relevant. In fact, studies show that even higher concentrations ( ≥150 nmol/L) were the most protective against breast cancer and associated with a decrease in risk.
Similar patterns are present for other labs, including iron studies, B12, magnesium, zinc, and inflammatory markers - all commonly misread in a cancer context. A comprehensive review found that micronutrient deficiencies are highly prevalent in cancer patients and are associated with worse treatment tolerance and poorer outcomes, yet remain underidentified using standard reference ranges.
Every patient I work with receives a thorough lab review - not just what's already been run, but what should be. Results are interpreted against optimal ranges, read as a pattern across the full picture, and assessed in the context that matters: treatment tolerance, recovery, and long-term risk reduction.
Functional Testing I Use
These tests go beyond standard panels to assess the systems that matter most in cancer; hormone metabolism, gut function, mineral status, mitochondrial health, and genetics.
The goal is never to run every test. It's to run the right test for this person, according to your stage, and your clinical picture.
-
The DUTCH test provides a detailed picture of sex hormone production and metabolism, and how estrogen is being broken down and cleared from the body.
Not all estrogen metabolites carry the same risk profile. The ratio of 2-hydroxyestrone to 16α-hydroxyestrone has been studied in relation to breast cancer risk, and the methylation pathway producing 2-methoxyestrone is considered protective. Knowing which pathways are dominant (and whether they're working efficiently) is genuinely useful clinical information at every stage of breast cancer care.
For women focused on risk reduction, the DUTCH provides a baseline picture of estrogen metabolism that can be actively improved through diet, lifestyle, and targeted support.
For women in active treatment on aromatase inhibitors or other hormone-blocking therapies, it shows how well estrogen is being suppressed and whether detoxification pathways are functioning optimally alongside treatment.
For women post-treatment, it supports ongoing monitoring of the hormonal environment - one of the most relevant factors in long-term recurrence risk reduction.
-
The OAT measures metabolic byproducts in urine that reflect mitochondrial function, gut microbial activity, neurotransmitter metabolism, and nutrient cofactor status. It's particularly useful for unpacking cancer-related fatigue, cognitive symptoms, and the metabolic toll of treatment.
Mitochondrial dysfunction is increasingly recognized as both a contributor to cancer biology and a consequence of certain chemotherapy agents. The OAT offers a functional window into this that standard panels don't provide.
-
The gut microbiome influences immune regulation, inflammatory signaling, estrogen metabolism, and response to cancer treatment itself.
A landmark 2018 study found that gut microbiome composition predicted response to PD-1 checkpoint inhibitor immunotherapy, with patients carrying higher microbial diversity showing significantly better outcomes.
The estrobolome (the collection of gut bacteria responsible for estrogen recycling) is directly relevant in hormone-sensitive cancers. Dysbiosis in this system can increase circulating estrogen levels independent of ovarian production.
Microbiome testing allows us to assess diversity, identify dysbiosis patterns, and target the protocol accordingly.
-
HTMA measures mineral levels and heavy metal burden accumulated in hair tissue over approximately three months, providing a longer-term picture than serum testing. It is most useful for assessing mineral ratios and identifying heavy metal accumulation that may be contributing to immune or metabolic dysfunction.
Heavy metal burden is particularly relevant in a cancer context. Certain chemotherapy agents, platinum-based treatments especially are associated with increased heavy metal accumulation in tissue post-treatment.
Elevated heavy metal concentrations are also independently associated with increased cancer risk, making assessment relevant not only after treatment but as part of proactive cancer risk reduction.
I use HTMA as one data point within a broader picture, and I'm transparent with patients about where its evidence base is stronger and where it requires careful interpretation.
-
This isn't a separate blood draw, it's a different way of reading the results you likely already have. Using optimal ranges rather than pathological cutoffs, and tracking markers across time rather than in isolation, functional blood chemistry interpretation can identify patterns that standard reporting misses entirely.
I review full blood counts, metabolic panels, thyroid function, inflammatory markers, iron studies, and key nutrients. I also analyze the picture they form together, not each result independently.
-
Genetic testing in an integrative oncology context is not just about identifying mutations (your oncologist manages that conversation). It's about understanding how your genes impact your nutrient levels, detoxification, and inflammatory signaling, and using that information to make smarter decisions about diet and supplementation.
Variants in genes like MTHFR, COMT, and VDR influence folate metabolism, estrogen clearance, and vitamin D receptor function respectively - all relevant in cancer care.
Importantly, genetic variants are not fixed outcomes. This is where epigenetics becomes clinically useful: gene expression is regulated by environmental signals (including diet, stress, toxic exposures, and lifestyle factors) which means the same variant can behave very differently depending on our nutrition and lifestyle choices.
Ongoing Monitoring: The Advantage of Continuity
Testing at one point in time is useful. Testing across time, with someone who holds the whole picture, is where the real clinical value sits.
When you work with me, I'm not handing you a report and stepping back. I'm tracking your conventional and functional results across the entire time we work together.
-
Your oncologist manages your tumor. Your GP manages your general health. Your specialist manages their system. In most cases, nobody is holding all of it together and watching for patterns across your whole picture.
That's what I do. Conventional labs, functional test results, treatment changes, symptoms, and your reported experience - all of it, tracked longitudinally.
Research consistently identifies fragmented care as a significant contributor to poorer outcomes and lower quality of life in cancer patients.
-
Every month, patients complete COMPASS (Cancer Outcomes Monitor: Physical, Psychosocial and Spiritual Scale). This is a structured outcomes tool I developed based on the validated PROMIS-29 framework, adapted specifically for people navigating cancer.
COMPASS tracks physical function, psychosocial wellbeing, and spiritual health across time. The monthly frequency means we're generating longitudinal data — not a one-time snapshot — so I can see trajectory, not just status.
The PROMIS-29 has strong psychometric validation across chronic illness populations.
COMPASS extends this framework to include the spiritual dimension of cancer experience, which is consistently identified as clinically meaningful in oncology patient-reported outcome research.
-
Every treatment has a known side effect profile, and I keep that profile in mind from the beginning of our work together, as a clinical map.
Some examples of what this looks like in practice: patients on somatostatin analogues (such as Sandostatin, used in neuroendocrine tumors) can develop progressive glucose dysregulation and gallbladder complications. These are changes that may not be flagged until they become symptomatic in a standard oncology review. Certain chemotherapy agents are associated with fat-soluble vitamin depletion that compounds over time. Aromatase inhibitors affect bone turnover in ways that interact with vitamin D and calcium status.
I'm watching for early signals in labs and symptoms, not waiting for a problem to declare itself.
By the time a side effect appears in a crisis appointment, it has often been developing for weeks or months. Early pattern recognition changes what's possible.
-
I'm not a replacement for your oncologist, GP, or specialist. I'm the clinician with the longitudinal view — tracking the whole picture across time, across systems, and across the course of your treatment and recovery.
When I notice something relevant, I document it clearly so you can bring it to your treating team. That's the collaboration.
"Specialists see one system. I watch the whole picture - across every visit, every result, every change."
— Camille Hoffman, Integrative oncology naturopath
Advanced Oncology Testing
These tests sit at the cutting edge of oncology research; evidence-based, increasingly available, and already being used by integrative practitioners (while the broader medical system catches up). For the right person at the right time, they can meaningfully change what's possible.
-
A liquid biopsy detects circulating tumor DNA (ctDNA) - fragments of genetic material shed by cancer cells into the bloodstream. It can identify tumor-specific mutations, monitor treatment response, and in some cases detect signs of recurrence earlier than conventional imaging.
It is ordered and interpreted in coordination with your oncology team, and is most useful as a monitoring tool rather than a primary diagnostic.
-
RGCC (Research Genetic Cancer Centre) offers two advanced tests that assess how an individual's circulating tumor cells (CTCs) respond to specific compounds — both natural and pharmaceutical.
Onconomics Extracts tests the sensitivity of your CTCs to 50 natural substances and plant extracts, identifying which compounds may be most effective for your specific cancer profile. This takes the guesswork out of botanical selection in integrative oncology — rather than applying general evidence, we're working with information about your actual tumor cells.
Onconomics Plus extends this to include chemotherapy agents, targeted therapies, and radiotherapy sensitivity, alongside a gene expression profile. It tests CTC response to 102 cytotoxic drugs and provides data that may support treatment planning conversations between patients and their oncologists. Any decisions about chemotherapy or targeted therapy remain entirely at the discretion of the treating oncologist.
Both tests quantify the number of circulating tumor cells detected — itself a clinically useful monitoring data point.
Honest limitations: Results reflect CTC behavior at a single point in time and may not capture the full complexity of tumor heterogeneity. In vitro sensitivity does not guarantee identical in vivo response. There is a lead time of several weeks, which may not suit patients with urgent treatment decisions. Cost is significant and is not covered by public funding or most private insurers — discussed individually during consultation.
These tests are best used as one informed input within a broader integrative strategy, interpreted by an experienced practitioner and discussed alongside your oncologist's recommendations.
What Happens With Your Results
A result without a plan is just a number.
When testing identifies a pattern (nutrient or hormonal imbalances, microbiome disruption, inflammatory driver) there is a lot we can do to restore balance.
Recommendations may include dietary changes, supplementation, lifestyle habits, further investigations, or a conversation with your oncology team, depending on what the picture shows.
But the more important work moves beyond the first step of correcting those imbalances, and actually understanding why they are out of balance in the first place.
That shift - from correcting a value to understanding its cause - is where real long-term change happens, and where we often find and fix things that weren't yet on the radar.
Not sure which tests are relevant for where you are right now? That's a good question for a free call.
Questions I'm Often Asked
-
No, and I wouldn't recommend it. The value of functional testing is in selecting the right tests for your specific situation, not running a comprehensive panel for its own sake. What's relevant depends on your diagnosis, where you are in treatment, your symptoms, and what we're trying to understand. We work out what's useful together.
-
The blood draw is often identical, the difference is in how results are interpreted. Standard labs flag results outside pathological ranges. Functional interpretation applies optimal ranges, tracks trends across time, and looks at the pattern markers form together rather than each result in isolation. The same result can tell a very different story depending on which lens you use.
-
Some. Functional blood chemistry uses standard labs your GP can order, however, we interpret them differently. Others, like the DUTCH test, OAT, HTMA, and microbiome testing, are specialty tests ordered through naturopathic and integrative practitioners. RGCC testing is ordered through a small number of practitioners globally. I can order or facilitate all of the tests listed on this page.
-
COMPASS (Cancer Outcomes Monitor: Physical, Psychosocial and Spiritual Scale) is a structured outcomes tool I developed based on the validated PROMIS-29 framework, adapted specifically for people navigating cancer. Completing it monthly means we're tracking how you're trending across physical function, psychosocial wellbeing, and spiritual health. That longitudinal data is clinically useful in a way a single snapshot isn't.
-
That depends on your situation, which is why I discuss it individually rather than list it as a standard recommendation. For some patients, particularly those with treatment-resistant cancer or those wanting to make more informed decisions about botanical selection, it provides genuinely useful data. For others, it may not change the clinical approach significantly. I'll tell you honestly whether I think it's worth pursuing in your case.
-
I do. One of the practical advantages of working with an integrative oncology practitioner is that someone is holding the whole picture, your oncology labs, functional test results, COMPASS data, symptoms, and treatment changes. All in one place, across time. Your oncologist manages your tumor. I track the whole system.
-
Many oncologists are increasingly familiar with integrative oncology and functional testing, particularly liquid biopsy and microbiome research, which have strong conventional evidence bases. For functional tests like the DUTCH or OAT, most oncologists are not aware of them or familiar with their clinical role. My role is to bring relevant findings to your attention clearly, so you can have informed conversations with them.
This information is educational only and does not replace advice from your oncology or medical team. | Last reviewed by Camille Hoffman, June 2026
Join the mailing list
For occasional emails on the latest in integrative oncology research, breast health, and practical ways to build resilience